Daluphar SA
4.3 FTEThe score of Daluphar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -57 % Total assets +47 % Headcount (avg FTE) +39 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Daluphar's annual accounts
| 2025 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Net result | −30,135 € | ||||
| Equity | 74,439 € | ||||
| Cash | 20,226 € | ||||
| EBITDA | −23,477 € | ||||
| Total assets | 651,365 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Sep 2026
- Year ended 31 Dec 2023filed on 30 Jul 2024
- Year ended 31 Dec 2022filed on 30 Aug 2023
- Year ended 31 Dec 2021filed on 26 Aug 2022
- Year ended 31 Dec 2020filed on 20 Aug 2021
Daluphar's financial analysis
- Solvency11.4%sector median: 37.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Daluphar
Daluphar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0860.093.852
- VAT number
- BE0860093852
- Peppol
- Registered · 0208:0860093852 · as of 08 Nov 2026
- Legal form
- SA
- Incorporated
- 14 Aug 2003
- Registered office
- 1070 Anderlecht
- Size
- Micro · 4.3 FTE
- Latest accounts
- 2025 · filed on 30 Sep 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Daluphar (SA) has been based in Anderlecht since 2003, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 30,135 € and equity of 74,439 €; its revenue is not published. With 4.3 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 11.4%, below the median of its sector (37.8%).
Companies similar to Daluphar
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie de Cherain Retail sale of pharmaceutical products Gouvy · balance sheet 658,226 €
- Apotheek G. Burtin Retail sale of pharmaceutical products Tessenderlo-Ham · balance sheet 651,210 €
- RAF BEX Retail sale of pharmaceutical products Leuven · balance sheet 651,970 €
- Curavaleas Retail sale of pharmaceutical products Antwerp · balance sheet 650,626 €
- Apoteek Staes Retail sale of pharmaceutical products Diest · balance sheet 650,270 €
- Humbeek Pharma Retail sale of pharmaceutical products Grimbergen · balance sheet 653,604 €
- PharmaSil Retail sale of pharmaceutical products Antwerp · balance sheet 648,028 €
- Geva Pharma Retail sale of pharmaceutical products Oudenaarde · balance sheet 655,182 €
Frequently asked questions about Daluphar
What is the revenue of Daluphar?
Daluphar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Daluphar?
In Belgium, the VAT number is the company number prefixed with BE: BE0860093852 for Daluphar, if the company is VAT-registered. Its company number (CBE) is 0860.093.852.
Where is the registered office of Daluphar?
According to the CBE register, the registered office of Daluphar is in 1070 Anderlecht.
What is the equity of Daluphar?
At the close of the 2025 financial year, the equity of Daluphar amounts to 74,439 €, a solvency of 11.4% of total assets.
How many people work at Daluphar?
4.3 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Daluphar?
The register lists 2 active mandates at Daluphar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Daluphar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →